Shanghai No 1 Pharmacy Co (SHSE:600833) Risk Assessment

View and export this data going back to 1994. Start your Free Trial

What is Shanghai No 1 Pharmacy Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shanghai No 1 Pharmacy Co is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Shanghai No 1 Pharmacy Co's Risk Assessment

For the Pharmaceutical Retailers subindustry, Shanghai No 1 Pharmacy Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai No 1 Pharmacy Co's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Shanghai No 1 Pharmacy Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shanghai No 1 Pharmacy Co's Risk Assessment falls into.

Shanghai No 1 Pharmacy Co (SHSE:600833) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shanghai No 1 Pharmacy Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Shanghai No 1 Pharmacy Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai No 1 Pharmacy Co (SHSE:600833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Shanghai No 1 Pharmacy Co Ltd (SHSE:600833) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 616 Nanjing East Road, Huangpu District, Shanghai, CHN, 200032

Website

http://www.dyyy.com.cn

Shanghai No 1 Pharmacy Co Ltd is engaged in pharmaceutical retail and wholesale in China. The company's product profile include Lei Shi Pearl Powder, Tongrentang Ejiao Powder, Wanshuntang Yangyin mouth fragrance mixture, and others. It also provides Nourishing health Nutrition, Medical instruments, Rehabilitation care, Contact lens, and others.

Executives

Xu Zi Ying

Director

Shanghai No 1 Pharmacy Co (SHSE:600833) Headlines

No Headlines